 Highland Grow is currently profitable on an EBITDA basis and the Transaction is expected to be immediately accretive to IMC Highland Grow is expected to generate net revenue of 29 million and 38 million and gross margins of 34 to 36 in 2021 and 2022, respectively1 Purchase price implies 2.3x net revenue and 6.7x EBITDA in 2022 with synergies MYM shareholders will receive 0.022 IMC shares for each MYM share, representing a price of 0.195 based on respective closing prices on March 31, 2021 Super premium positioning, complementary brands, enhanced distribution and export opportunities to Israel and European markets TORONTO, ON, VANCOUVER, BC, and GLIL YAM, ISRAEL ACCESSWIRE April 1, 2021 IM Cannabis Corp. the Company or IMC NASDAQ:IMCC CSE:IMCC, a multi-country operator MCO in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada is pleased to announce that it has entered into a definitive agreement the Arrangement Agreement to acquire MYM Nutraceuticals Inc. MYM and its licensed producer subsidiary Highland Grow Inc. Highland Grow, pursuant to a plan of arrangement to be completed under the Business Corporations Act British Columbia the Transaction. The Transaction reinforces the Companys strategy as a leading global premium cannabis producer and purveyor. 